Show all abstracts Show selected abstracts Add to my list
Perspective: Therapeutic prevention of colorectal carcinogenesis
Frank L MeyskensJ Carcinog 2011, 10:13 (16 April 2011)DOI :10.4103/1477-3163.79682 PMID :21712960
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (2) ] [PubMed] [Sword Plugin for Repository] Beta
Review Article: Statistical methods for assays with limits of detection: Serum bile acid as a differentiator between patients with normal colons, adenomas, and colorectal cancer
Bonnie LaFleur, Wooin Lee, Dean Billhiemer, Craig Lockhart, Junmei Liu, Nipun MerchantJ Carcinog 2011, 10:12 (16 April 2011)DOI :10.4103/1477-3163.79681 PMID :21712958In analytic chemistry a detection limit (DL) is the lowest measurable amount of an analyte that can be distinguished from a blank; many biomedical measurement technologies exhibit this property. From a statistical perspective, these data present inferential challenges because instead of precise measures, one only has information that the value is somewhere between 0 and the DL (below detection limit, BDL). Substitution of BDL values, with 0 or the DL can lead to biased parameter estimates and a loss of statistical power. Statistical methods that make adjustments when dealing with these types of data, often called left-censored data, are available in many commercial statistical packages. Despite this availability, the use of these methods is still not widespread in biomedical literature. We have reviewed the statistical approaches of dealing with BDL values, and used simulations to examine the performance of the commonly used substitution methods and the most widely available statistical methods. We have illustrated these methods using a study undertaken at the Vanderbilt-Ingram Cancer Center, to examine the serum bile acid levels in patients with colorectal cancer and adenoma. We have found that the modern methods for BDL values identify disease-related differences that are often missed, with statistically naive approaches.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [PubMed] [Sword Plugin for Repository] Beta
Editorial Commentary: Perspective: Chemoprevention of colorectal neoplasia: Translating scientific promise into clinical practice
Peter Lance, Patricia A ThompsonJ Carcinog 2011, 10:11 (16 April 2011)DOI :10.4103/1477-3163.79674 PMID :21712959
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (1) ] [PubMed] [Sword Plugin for Repository] Beta
Review Article: Defining the role of polyamines in colon carcinogenesis using mouse models
Natalia A Ignatenko, Eugene W Gerner, David G BesselsenJ Carcinog 2011, 10:10 (16 April 2011)DOI :10.4103/1477-3163.79673 PMID :21712957Genetics and diet are both considered important risk determinants for colorectal cancer, a leading cause of death in the US and worldwide. Genetically engineered mouse (GEM) models have made a significant contribution to the characterization of colorectal cancer risk factors. Reliable, reproducible, and clinically relevant animal models help in the identification of the molecular events associated with disease progression and in the development of effictive treatment strategies. This review is focused on the use of mouse models for studying the role of polyamines in colon carcinogenesis. We describe how the available mouse models of colon cancer such as the multiple intestinal neoplasia (Min) mice and knockout genetic models facilitate understanding of the role of polyamines in colon carcinogenesis and help in the development of a rational strategy for colon cancer chemoprevention.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (2) ] [PubMed] [Sword Plugin for Repository] Beta
Review Article: The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies
Mariangela De Robertis, Emanuela Massi, Maria Luana Poeta, Simone Carotti, Sergio Morini, Loredana Cecchetelli, Emanuela Signori, Vito Michele FazioJ Carcinog 2011, 10:9 (24 March 2011)DOI :10.4103/1477-3163.78279 PMID :21483655Colorectal cancer (CRC) is a major health problem in industrialized countries. Although inflammation-linked carcinogenesis is a well accepted concept and is often observed within the gastrointestinal tract, the underlying mechanisms remain to be elucidated. Inflammation can indeed provide initiating and promoting stimuli and mediators, generating a tumour-prone microenvironment. Many murine models of sporadic and inflammation-related colon carcinogenesis have been developed in the last decade, including chemically induced CRC models, genetically engineered mouse models, and xenoplants. Among the chemically induced CRC models, the combination of a single hit of azoxymethane (AOM) with 1 week exposure to the inflammatory agent dextran sodium sulphate (DSS) in rodents has proven to dramatically shorten the latency time for induction of CRC and to rapidly recapitulate the aberrant crypt foci-adenoma-carcinoma sequence that occurs in human CRC. Because of its high reproducibility and potency, as well as the simple and affordable mode of application, the AOM/DSS has become an outstanding model for studying colon carcinogenesis and a powerful platform for chemopreventive intervention studies. In this article we highlight the histopathological and molecular features and describe the principal genetic and epigenetic alterations and inflammatory pathways involved in carcinogenesis in AOM/DSS-treated mice; we also present a general overview of recent experimental applications and preclinical testing of novel therapeutics in the AOM/DSS model.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (28) ] [PubMed] [Sword Plugin for Repository] Beta
Perspective: Clinical trials update: Tertiary prevention of colorectal cancer
Jason A ZellJ Carcinog 2011, 10:8 (24 March 2011)DOI :10.4103/1477-3163.78271 PMID :21483656
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (4) ] [PubMed] [Sword Plugin for Repository] Beta
Original Article: Systematic enrichment analysis of gene expression profiling studies identifies consensus pathways implicated in colorectal cancer development
Jesús Lascorz, Kari Hemminki, Asta FörstiJ Carcinog 2011, 10:7 (24 March 2011)DOI :10.4103/1477-3163.78268 PMID :21483658Background: A large number of gene expression profiling (GEP) studies on colorectal carcinogenesis have been performed but no reliable gene signature has been identified so far due to the lack of reproducibility in the reported genes. There is growing evidence that functionally related genes, rather than individual genes, contribute to the etiology of complex traits. We used, as a novel approach, pathway enrichment tools to define functionally related genes that are consistently up- or down-regulated in colorectal carcinogenesis. Materials and Methods: We started the analysis with 242 unique annotated genes that had been reported by any of three recent meta-analyses covering GEP studies on genes differentially expressed in carcinoma vs normal mucosa. Most of these genes (218, 91.9%) had been reported in at least three GEP studies. These 242 genes were submitted to bioinformatic analysis using a total of nine tools to detect enrichment of Gene Ontology (GO) categories or Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. As a final consistency criterion the pathway categories had to be enriched by several tools to be taken into consideration. Results: Our pathway-based enrichment analysis identified the categories of ribosomal protein constituents, extracellular matrix receptor interaction, carbonic anhydrase isozymes, and a general category related to inflammation and cellular response as significantly and consistently overrepresented entities. Conclusions: We triaged the genes covered by the published GEP literature on colorectal carcinogenesis and subjected them to multiple enrichment tools in order to identify the consistently enriched gene categories. These turned out to have known functional relationships to cancer development and thus deserve further investigation.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (2) ] [PubMed] [Sword Plugin for Repository] Beta
Original Article: Risk of second primary colorectal cancer among colorectal cancer cases: A population-based analysis
Kavitha P Raj, Thomas H Taylor, Charlie Wray, Michael J Stamos, Jason A ZellJ Carcinog 2011, 10:6 (17 March 2011)DOI :10.4103/1477-3163.78114 PMID :21483654Background: Patients with history of colorectal cancer (CRC) are at increased risk for developing a second primary colorectal cancer (SPCRC) as compared to the general population. However, the degree of risk is uncertain. Here, we attempt to quantify the risk, using data from the large population-based California Cancer Registry (CCR). Materials and Methods: We analyzed the CCR data for cases with surgically-treated colon and rectal cancer diagnosed during the period 1990-2005 and followed through up to January 2008. We excluded those patients diagnosed with metastatic disease and those in whom SPCRC was diagnosed within 6 months of the diagnosis of the primary CRC. Standardized incidence ratios (SIR) with 95% confidence intervals (CI) were calculated to evaluate risk as compared to the underlying population after taking into account age, sex, ethnicity, and time at risk. Results: The study cohort consisted of 69809 cases with colon cancer and 34448 with rectal cancer. Among these patients there were 1443 cases of SPCRCs. The SIR for developing SPCRC was higher in colon cancer survivors (SIR=1.4; 95% CI: 1.3 to 1.5) as compared to the underlying population. The incidence of SPCRC was also higher in females (SIR=1.5; 95% CI: 1.3 to 1.6) and Hispanics (SIR=2.0; 95% CI: 1.7 to 2.4) with primary colon cancer. The SIR for developing an SPCRC was higher only among those whose initial tumor was located in the descending colon (SIR=1.6; 95% CI: 1.3 to 2.0) and proximal colon (SIR=1.4; 95% CI: 1.3 to 1.6). Conclusions: Our results confirm that CRC patients, especially females and Hispanics, are at a higher risk of developing SPCRC than the general population. Differential SPCRC risk by colorectal tumor subsite is dependent on gender and ethnicity, underscoring the heterogeneous nature of CRC.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (12) ] [PubMed] [Sword Plugin for Repository] Beta
Review Article: Wnt signaling and colon carcinogenesis: Beyond APC
Rani Najdi, Randall F Holcombe, Marian L WatermanJ Carcinog 2011, 10:5 (17 March 2011)DOI :10.4103/1477-3163.78111 PMID :21483657Activation of the Wnt signaling pathway via mutation of the adenomatous polyposis coli gene (APC) is a critical event in the development of colon cancer. For colon carcinogenesis, however, constitutive signaling through the canonical Wnt pathway is not a singular event. Here we review how canonical Wnt signaling is modulated by intracellular LEF/TCF composition and location, the action of different Wnt ligands, and the secretion of Wnt inhibitory molecules. We also review the contributions of non-canonical Wnt signaling and other distinct pathways in the tumor micro environment that cross-talk to the canonical Wnt pathway and thereby influence colon cancer progression. These 'non-APC' aspects of Wnt signaling are considered in relation to the development of potential agents for the treatment of patients with colon cancer. Regulatory pathways that influence Wnt signaling highlight how it might be possible to design therapies that target a network of signals beyond that of APC and β-catenin.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (41) ] [PubMed] [Sword Plugin for Repository] Beta
Special Issues: Circulating fibroblast growth factor-23 is associated with increased risk for metachronous colorectal adenoma
Elizabeth Jacobs, Maria Elena Martinez, Julie Buckmeier, Peter Lance, Melissa May, Peter JurutkaJ Carcinog 2011, 10:3 (12 February 2011)DOI :10.4103/1477-3163.76723 PMID :21383962Background: Fibroblast growth factor-23 (FGF-23) is a phosphaturic peptide and a key component of an endocrine feedback loop along with the hormonal vitamin D metabolite 1,25(OH) 2 D. Vitamin D has been shown to be inversely related to colorectal neoplasia; therefore, we hypothesized that the effect of FGF-23 on vitamin D metabolite concentrations could have implications for the risk of colorectal neoplasia. Materials and Methods: The purpose of this study was to prospectively evaluate the association between circulating concentrations of FGF-23 and the risk of metachronous (recurrent) colorectal adenomas. FGF-23 levels were assessed in 100 male and female participants from the Ursodeoxycholic Acid Trial, 50 of whom had a metachronous colorectal adenoma and 50 who did not. Results: Compared to the lowest tertile of FGF-23, the adjusted odds ratios (95% CIs) for the second and third tertiles were 2.80 (0.94 to 8.31) and 3.41 (1.09 to 10.67), respectively (P -trend=.03). In a linear regression model, there was also a statistically significant inverse relationship between FGF-23 and 1,25(OH) 2 D (β-coefficient=-1.2; P =.001). In contrast, no statistically significant trend was observed between FGF-23 and 25(OH)D concentrations (β-coefficient=0.55; P =.10). Conclusions: The current work presents novel preliminary evidence of a relationship between FGF-23 and the risk for colorectal neoplasia. FGF-23 activity may be mediated through biologic effects on individual serum and colonic 1,25(OH) 2 D levels, or it may be independent from the vitamin D pathway. Further studies in larger populations are necessary for confirmation and expansion of these hypothesis-generating results.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (7) ] [PubMed] [Sword Plugin for Repository] Beta